Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma

Supporting evidence

• Review decision

• Static List Review – April 2016

• Appendix A – Static List Review Paper (PDF 248 KB)

  Published:

  24 April 2016